A Comparison of Two Anti-HIV Triple-Drug Combinations in HIV-Infected Patients
Launched by BRISTOL-MYERS SQUIBB · Aug 30, 2001
Trial Information
Current as of July 01, 2025
Completed
Keywords
ClinConnect Summary
100 patients will be randomized to receive Zerit (Stavudine) + Videx (Didanosine) + Crixivan (Indinavir) and 100 patients will be randomized to receive Retrovir (Zidovudine) + Epivir (Lamivudine) + Crixivan (Indinavir).
Patients will be treated for 48 weeks.
Gender
ALL
Eligibility criteria
- • Inclusion Criteria
- Patients must have:
- • Documented HIV infection.
- • CD4 cell count of 200 - 700 cells/mm3.
- • Exclusion Criteria
- Co-existing Condition:
- Patients with the following symptoms or conditions are excluded:
- • AIDS defining condition within 1 month of study entry.
- Prior Medication:
- Excluded:
- • Patients with any history of antiretroviral therapy treatment.
About Bristol Myers Squibb
Bristol-Myers Squibb (BMS) is a global biopharmaceutical company dedicated to discovering, developing, and delivering innovative medicines that help patients prevail over serious diseases. With a robust portfolio of products across multiple therapeutic areas, including oncology, immunology, cardiovascular, and fibrotic diseases, BMS emphasizes cutting-edge research and a commitment to advancing medical science through clinical trials. The company is driven by a mission to provide transformative therapies, leveraging collaboration and scientific expertise to address unmet medical needs and improve patient outcomes worldwide.
Contacts
Jennifer Cobb
Immunology at National Institute of Allergy and Infectious Diseases (NIAID)
Locations
Dallas, Texas, United States
Chicago, Illinois, United States
Chicago, Illinois, United States
Berkeley, California, United States
Torrance, California, United States
Washington, District Of Columbia, United States
Washington, District Of Columbia, United States
Omaha, Nebraska, United States
Chapel Hill, North Carolina, United States
Charlotte, North Carolina, United States
Philadelphia, Pennsylvania, United States
Dallas, Texas, United States
Ponce, , Puerto Rico
Patients applied
Timeline
First submit
Trial launched
Trial updated
Estimated completion
Not reported
Similar Trials